User profiles for JS Nguyen-Van-Tam
 | Jonathan Van TamProfessor of Health Protection, University of Nottingham Verified email at nottingham.ac.uk Cited by 25388 |
Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study
Objective To characterise the clinical features of patients admitted to hospital with coronavirus
disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave …
disease 2019 (covid-19) in the United Kingdom during the growth phase of the first wave …
[HTML][HTML] Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV …
Background Few data exist on the comparative safety and immunogenicity of different
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
COVID-19 vaccines given as a third (booster) dose. To generate data to optimise selection of …
Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: development and validation of the 4C …
… A Green,9 Rishi Gupta,10 Sophie Halpin,8 Hayley E Hardwick,11 Karl A Holden,11 Peter
W Horby,5 Clare Jackson,8 Kenneth A Mclean,1 Laura Merson,5 Jonathan S Nguyen-Van-Tam…
W Horby,5 Clare Jackson,8 Kenneth A Mclean,1 Laura Merson,5 Jonathan S Nguyen-Van-Tam…
[HTML][HTML] Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults
…, C Charman, P Mande, JS Nguyen-Van-Tam… - Nature Medicine, 2022 - nature.com
… , to ensure continued support, we are displaying the site without styles and JavaScript. …
Nguyen-Van-Tam, JS et al. Minimal transmission in an influenza A (H3N2) human challenge-…
Nguyen-Van-Tam, JS et al. Minimal transmission in an influenza A (H3N2) human challenge-…
Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a …
…, PJ Turner, LL Walker, R White, JS Nguyen-Van-Tam… - The Lancet, 2021 - thelancet.com
Background Use of heterologous prime-boost COVID-19 vaccine schedules could facilitate
mass COVID-19 immunisation. However, we have previously reported that heterologous …
mass COVID-19 immunisation. However, we have previously reported that heterologous …
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic …
…, JS Nguyen-Van-Tam… - The Journal of …, 2015 - academic.oup.com
Background. Administration of convalescent plasma, serum, or hyperimmune immunoglobulin
may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of …
may be of clinical benefit for treatment of severe acute respiratory infections (SARIs) of …
Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study
…, L Sigfrid, IP Sinha, PL Olliaro, JS Nguyen-Van-Tam… - bmj, 2020 - bmj.com
Objective To characterise the clinical features of children and young people admitted to
hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
hospital with laboratory confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-…
Molnupiravir plus usual care versus usual care alone as early treatment for adults with COVID-19 at increased risk of adverse outcomes (PANORAMIC): an open-label …
…, S Khoo, S Petrou, K Hood, JS Nguyen-Van-Tam… - The Lancet, 2023 - thelancet.com
Background The safety, effectiveness, and cost-effectiveness of molnupiravir, an oral
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
antiviral medication for SARS-CoV-2, has not been established in vaccinated patients in the …
[HTML][HTML] Reduced neutralisation of SARS-CoV-2 omicron B. 1.1. 529 variant by post-immunisation serum
…, J Mongkolsapaya, JS Nguyen-Van-Tam… - Lancet (London …, 2022 - ncbi.nlm.nih.gov
According to WHO, SARS-CoV-2 is estimated to have caused 265 million infections and
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
more than 5 million deaths over the past 2 years. Current vaccines are based on the original …
Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study
Objectives To derive and validate risk prediction algorithms to estimate the risk of covid-19
related mortality and hospital admission in UK adults after one or two doses of covid-19 …
related mortality and hospital admission in UK adults after one or two doses of covid-19 …
